CN106511371A - 一种复合益生元及其应用 - Google Patents
一种复合益生元及其应用 Download PDFInfo
- Publication number
- CN106511371A CN106511371A CN201610982929.8A CN201610982929A CN106511371A CN 106511371 A CN106511371 A CN 106511371A CN 201610982929 A CN201610982929 A CN 201610982929A CN 106511371 A CN106511371 A CN 106511371A
- Authority
- CN
- China
- Prior art keywords
- long
- product
- chain inulin
- prebiotic
- colon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title abstract description 6
- 229920001202 Inulin Polymers 0.000 claims abstract description 28
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 26
- 229940029339 inulin Drugs 0.000 claims abstract description 26
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000010521 absorption reaction Methods 0.000 claims abstract description 3
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 3
- 239000011575 calcium Substances 0.000 claims abstract description 3
- 229930182830 galactose Natural products 0.000 claims description 15
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 210000001731 descending colon Anatomy 0.000 abstract description 12
- 210000001815 ascending colon Anatomy 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 210000002429 large intestine Anatomy 0.000 abstract description 3
- 238000005457 optimization Methods 0.000 abstract description 3
- 230000037358 bacterial metabolism Effects 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 2
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract 2
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical group C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 229920000377 Sinistrin Polymers 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种复合益生元,按重量百分比由长链菊粉30‑70%、低聚半乳糖15‑40%及低聚果糖15‑40%组成,该长链菊粉由10‑60个果糖单位聚合而成。本发明的复合益生元产品中引入长链菊粉、并与低聚果糖和低聚半乳糖配伍组合,使产品在升结肠、降结肠等区域均能发酵,能全方位作用于整个大肠,既有菌群优化功能,又可促进细菌代谢;能促进钙质吸收,提高机体免疫力,改善对感染的抵抗力,降低癌症风险等功能均显著高于其它益生元产品。本复合益生元产品可作为饮料、普通食品、保健食品、特殊医学用途配方食品和药品的原料或配料使用。
Description
技术领域
本发明涉及一种复合益生元,具体涉及一种由长链菊粉配伍低聚半乳糖和低聚果糖组成的复合益生元,同时还涉及该复合益生元在抗肿瘤中的作用。
背景技术
益生元是一种现代饮食中被丢失的、对人体健康有益的膳食纤维,是一种可被选择性发酵并改变胃肠道中对宿主健康有益菌群的组成和活性的食物成分。益生元必须满足三个条件:1、耐酸和水解酶,不被胃与小肠消化吸收;2、可被肠道菌群发酵;3、能选择性地刺激双歧杆菌和乳酸杆菌等肠道有益菌的生长。
目前应用较多的益生元主要是低聚糖类物质,如低聚半乳糖、菊粉、低聚果糖、低聚木糖、低聚异麦芽糖、大豆低聚糖、壳聚糖等。该些益生元制成的益生元产品具有如下缺点:
1、目前市场上的益生元产品都集中在升结肠部位快速发酵,而缺乏能在降结肠中滞留并缓慢发酵的益生元。我们知道,在降结肠中储存了大量的粪便,腔内高度腐败,许多代谢终产物如氨、胺类和酚类化合物对宿主是有毒的;同时,降结肠中剩余的益生元等碳水化合物已经极少,削弱了益生菌等细菌的代谢,从而引发许多疾病。
2、目前市场上益生元产品多以单方益生元为主,但是单方产品局限性极大;或是以极小剂量益生元与益生菌配伍成合生元产品,但是这类产品中益生元因含量太少难以起到应有生理功能,皆是由于不同的益生元有着各自独特的个性(如对各种益生菌的促进作用不同;对各种有害菌群的抑制能力不同;发酵的时间长短不同,导致在大肠内各区域的活性不同;发酵分解时产生的短链脂肪酸的种类和量不同等)造成。
因此,设计出在升结肠、降结肠等区域均能发酵,既有菌群优化功能,又可促进细菌代谢能力的复方益生元产品有着非常巨大的社会意义与市场前景。
发明内容
本发明所要解决的技术问题是:针对上述现有技术的不足,提供一种配方精简、功能齐全、安全天然且具协同增效的复合益生元及其应用。
为解决上述技术问题,本发明所采用的技术方案是:一种复合益生元,该复合益生元按重量百分比由长链菊粉30-70%、低聚半乳糖15-40%及低聚果糖15-40%组成,该长链菊粉由10-60个果糖单位聚合而成。
本发明的复合益生元是取低聚果糖和低聚半乳糖混合均匀,再加入长链菊粉,混合均匀制得。本复合益生元产品可作为饮料、普通食品、保健食品、特殊医学用途配方食品和药品的原料或配料使用。
本发明的复合益生元产品中革命性地引入长链菊粉(又称多聚果糖),长链菊粉聚合度大,由10-60个果糖单位聚合而成,在水中难以溶解,发酵速度缓慢,其主要发酵部位在降结肠,它对结肠末端的更多部位可起到有益作用,这是其它低聚糖类益生菌无法达成的。而且,其对细菌主要以影响代谢为主。长链菊粉与其它低聚糖配伍后,对骨结构的加强,调节机体免疫系统,降低癌症风险等,都明显优于其它益生元。产品中低聚果糖和低聚半乳糖因聚合度小、水溶性强、发酵快,主要在升结肠发酵,对双歧杆菌、乳杆菌等有很好的增殖能力,对大肠中菌群结构有很好的优化作用。本产品具有良好的协同增效作用,使产品的优化菌群、影响菌群代谢,加强宿主骨结构,提高机体免疫力,降低癌症风险等生理功能更为显著。
本复合益生元引入长链菊粉,并与低聚果糖和低聚半乳糖配伍组合,使产品在升结肠、降结肠等区域均能发酵,能全方位作用于整个大肠,既有菌群优化功能,又可促进细菌代谢;能促进钙质吸收,提高机体免疫力,改善对感染的抵抗力,降低癌症风险等功能均显著高于其它益生元产品,具体如下:
1.抗肿瘤作用:在肿瘤的化学预防模型试验中,取70只昆明种小鼠(由湘雅医学院实验动物学部提供,体重18~22g),用10mg/kg的重氮甲烷(AOM)注射至小鼠腹腔,诱发结肠的癌变。将小鼠随机分为7组(每组中雌雄各半),1组为空白对照组,其余6组每天分别喂饲含400mg低聚果糖、400mg低聚半乳糖、400mg长链菊粉、400mg长链菊粉+低聚半乳糖、400mg长链菊粉+低聚果糖,以及400mg本发明产品(低聚果糖+低聚半乳糖+长链菊粉)的饲料,8周后处死,取结肠,计数各组升结肠和降结肠中的ACF(畸形隐性病灶)群数,取平均值。结果见图1,显示:在升结肠和降结肠中,相对于对照组,其余6组的ACF群数皆有所降低,且本发明产品组即喂饲低聚果糖+低聚半乳糖+长链菊粉三联益生元的ACF数最低,其抗癌效果最好,表明本益生元产品具有极其良好的抗肿瘤协同增效作用。
附图说明
图1是本发明复合益生元抗肿瘤的ACF(畸形隐性病灶)群数图。
图中:升结肠是指各实验组在升结肠部位统计到的ACF数据;降结肠是指各实验组在降结肠部位统计到的ACF数据;总计是指各实验组在升结肠与降结肠两个部位统计到的所有的ACF数据。
具体实施方式
以下实施例中的长链菊粉由10-60个果糖单位聚合而成。长链菊粉、低聚半乳糖及低聚果糖皆为市购产品。
实施例1
按重量百分比取长链菊粉30%、低聚半乳糖40%及低聚果糖30%,先将低聚果糖与低聚半乳糖混匀后,再加入长链菊粉混匀,即得本发明的复合益生元产品。
实施例2
按重量百分比取长链菊粉40%、低聚半乳糖20%及低聚果糖40%,先将低聚果糖与低聚半乳糖混匀后,再加入长链菊粉混匀,即得本发明的复合益生元产品。
实施例3
按重量百分比取长链菊粉50%、低聚半乳糖30%及低聚果糖20%,先将低聚果糖与低聚半乳糖混匀后,再加入长链菊粉混匀,即得本发明的复合益生元产品。
实施例4
按重量百分比取长链菊粉70%、低聚半乳糖15%及低聚果糖15%,先将低聚果糖与低聚半乳糖混匀后,再加入长链菊粉混匀,即得本发明的复合益生元产品。
Claims (3)
1.一种复合益生元,其特征在于,该复合益生元按重量百分比由长链菊粉30-70%、低聚半乳糖15-40%及低聚果糖15-40%组成,该长链菊粉由10-60个果糖单位聚合而成。
2.权利要求1所述的复合益生元在促进钙质吸收中的应用。
3.权利要求1所述的复合益生元在抗肿瘤协同增效中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610982929.8A CN106511371A (zh) | 2016-11-09 | 2016-11-09 | 一种复合益生元及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610982929.8A CN106511371A (zh) | 2016-11-09 | 2016-11-09 | 一种复合益生元及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106511371A true CN106511371A (zh) | 2017-03-22 |
Family
ID=58350069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610982929.8A Pending CN106511371A (zh) | 2016-11-09 | 2016-11-09 | 一种复合益生元及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106511371A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111227261A (zh) * | 2020-01-21 | 2020-06-05 | 广东量子高科微生态医疗有限公司 | 一种益生元组合物及其应用 |
CN114586982A (zh) * | 2022-03-01 | 2022-06-07 | 武汉英纽林生物科技有限公司 | 一种改善妊娠期便秘的营养配方产品 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810222A (zh) * | 2010-04-23 | 2010-08-25 | 陕西农产品加工技术研究院 | 一种合生元羊奶粉 |
CN105942526A (zh) * | 2016-04-29 | 2016-09-21 | 上海知音堂生物科技有限公司 | 三维益生元 |
-
2016
- 2016-11-09 CN CN201610982929.8A patent/CN106511371A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810222A (zh) * | 2010-04-23 | 2010-08-25 | 陕西农产品加工技术研究院 | 一种合生元羊奶粉 |
CN105942526A (zh) * | 2016-04-29 | 2016-09-21 | 上海知音堂生物科技有限公司 | 三维益生元 |
Non-Patent Citations (3)
Title |
---|
任建林: "《整合胃肠黏膜病变任建林2016观点》", 31 May 2016 * |
凌关庭主编: "《保健食品原料手册》", 28 February 2002 * |
王德隆等: "《常见慢性病预防与控制》", 31 December 2014 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111227261A (zh) * | 2020-01-21 | 2020-06-05 | 广东量子高科微生态医疗有限公司 | 一种益生元组合物及其应用 |
CN114586982A (zh) * | 2022-03-01 | 2022-06-07 | 武汉英纽林生物科技有限公司 | 一种改善妊娠期便秘的营养配方产品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103549141B (zh) | 一种猪用中草药复合益生菌饲料添加剂及其制备方法 | |
Lauzon et al. | Probiotics and prebiotics: concepts, definitions and history | |
Flesch et al. | The therapeutic use of symbiotics | |
CN1229115C (zh) | 含有益生素物质的营养配方 | |
CN102106383B (zh) | 一种老鹰茶酸奶及其制备方法和用途 | |
CN104171421A (zh) | 一种用于调理动物肠道的饲料添加剂 | |
EP2608678A1 (en) | Synbiotic product | |
CN104222629A (zh) | 一种仔猪生物饲料添加剂 | |
CN103330059B (zh) | 一种兽用保健组合物及其制备方法和用途 | |
CN106539089A (zh) | 一种复合益生元及其应用 | |
WO2023116227A1 (zh) | 一种具有减肥功效的微生物组合及其应用 | |
CN108935698A (zh) | 一种预防小儿腹泻疾病的营养组合物及应用 | |
CN108541953A (zh) | 一种具有调节肠道微生物结构并增殖嗜黏蛋白阿卡曼氏菌的组合物 | |
CN102106925B (zh) | 枸杞多糖双歧杆菌合生元结肠靶向微生态调节剂 | |
CN106511371A (zh) | 一种复合益生元及其应用 | |
Patel et al. | Biological properties of xylooligosaccharides as an emerging prebiotic and future perspective | |
CN107889997A (zh) | 一种益生菌冻干粉固体饮料 | |
CN101297679A (zh) | 一种提高畜禽免疫力的饲料添加剂及其制备方法 | |
CN102920771B (zh) | 一种用于治疗家禽球虫病的药物 | |
CN107961260A (zh) | 治疗、预防禽类大肠杆菌性腹泻病的药剂及其制备方法 | |
US11478525B2 (en) | Method for promoting growth of Akkermansia muciniphila using musa ferments | |
CN104982717A (zh) | 一种肉仔鸡无抗日粮饲料添加剂预混料及使用方法 | |
CN107242579A (zh) | 一种复合益生元及其应用 | |
CN102687804B (zh) | 一种重组乳杆菌和中草药合生元、合生元制剂及用途 | |
CN104920809B (zh) | 一种改善母猪奶水中乳汁寡糖的饲料添加剂预混剂及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
RJ01 | Rejection of invention patent application after publication |